First week of social lockdown versus medical care against COVID-19 - with special reference to India

Q3 Pharmacology, Toxicology and Pharmaceutics Current Trends in Biotechnology and Pharmacy Pub Date : 2020-04-01 DOI:10.5530/ctbp.2020.2.20
Kabita Das, B. Paital
{"title":"First week of social lockdown versus medical care against COVID-19 - with special reference to India","authors":"Kabita Das, B. Paital","doi":"10.5530/ctbp.2020.2.20","DOIUrl":null,"url":null,"abstract":"The disease caused by Coronavirus (CoV) is called as Coronavirus Disease (COVID-19). It became pandemic in 210 countries and rolling data indicate that 2,606,635individuals are infected with the deadly pandemic disease and 713,812 have recovered, while, 182,114 have lost their lives. Although, few drugs namely Chloroquine, Hydr oxychl or oqui ne and Azi t hr omyci n, Tocilizumab, Lopinavir; Ritonavir and Tocilizumab are recommended on contextual basis for the treatment of COVID-19, the world is still waiting to come up with a specific vaccine or medicine to combat the disease. Without a specific medicine, countries such as Italy, USA, Spain and France, withthe most advanced health care systems are unsuccessful to control both the infection and death rate under COVID-19 infection. India being the world’s 2 ndlargest populous country, where, the health care system is under developed, with major portion of people live less-hygienic life, has contracted the disease at a slower rate as compared to the above countries. India has achieved this through employing social distancing by following a strict lockdown. This article is focused on social distancing of India and the kind of social interaction that can be adapted by people during lockdown.","PeriodicalId":10980,"journal":{"name":"Current Trends in Biotechnology and Pharmacy","volume":"14 1","pages":"196-216"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Trends in Biotechnology and Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5530/ctbp.2020.2.20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 22

Abstract

The disease caused by Coronavirus (CoV) is called as Coronavirus Disease (COVID-19). It became pandemic in 210 countries and rolling data indicate that 2,606,635individuals are infected with the deadly pandemic disease and 713,812 have recovered, while, 182,114 have lost their lives. Although, few drugs namely Chloroquine, Hydr oxychl or oqui ne and Azi t hr omyci n, Tocilizumab, Lopinavir; Ritonavir and Tocilizumab are recommended on contextual basis for the treatment of COVID-19, the world is still waiting to come up with a specific vaccine or medicine to combat the disease. Without a specific medicine, countries such as Italy, USA, Spain and France, withthe most advanced health care systems are unsuccessful to control both the infection and death rate under COVID-19 infection. India being the world’s 2 ndlargest populous country, where, the health care system is under developed, with major portion of people live less-hygienic life, has contracted the disease at a slower rate as compared to the above countries. India has achieved this through employing social distancing by following a strict lockdown. This article is focused on social distancing of India and the kind of social interaction that can be adapted by people during lockdown.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎社会封锁与医疗保健的第一周——特别是印度
由冠状病毒(CoV)引起的疾病称为冠状病毒病(COVID-19)。它在210个国家成为大流行病,滚动数据表明,有2,606,635人感染了这种致命的大流行病,713,812人已经康复,而182,114人丧生。虽然,很少有药物,即氯喹、羟氧基或奥喹、阿齐、托珠单抗、洛匹那韦;利托那韦和托珠单抗被推荐用于治疗COVID-19,世界仍在等待找到一种特定的疫苗或药物来对抗这种疾病。意大利、美国、西班牙和法国等拥有最先进卫生保健系统的国家在没有特定药物的情况下,无法控制COVID-19感染下的感染率和死亡率。印度是世界上人口第二大的国家,医疗保健系统不发达,大部分人的生活不太卫生,与上述国家相比,印度感染这种疾病的速度较慢。印度通过实施严格的封锁措施,保持社交距离,实现了这一目标。这篇文章的重点是印度的社交距离以及人们在封锁期间可以适应的社交互动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Trends in Biotechnology and Pharmacy
Current Trends in Biotechnology and Pharmacy Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
0.70
自引率
0.00%
发文量
0
期刊介绍: The Association of Biotechnology and Pharmacy (ABAP) will be useful to form a forum for scientists so that they can bring together to discuss and find scientific solutions to the problems of society. The annual meetings will help the members to share their knowledge and publish their research knowledge particularly by members and fellows of the Association and special care will be taken to provide an opportunity for young scientists. Besides this the association is planned to organize symposia, seminars and workshops on current developments of Biotechnology and Pharmacy particularly on the subject of current scientific interest, and the proceedings of which will be published regularly. And in view of the vast development of science and to disseminate the problems in publication of research work, an international journal of Current Trends in Biotechnology and Pharmacy has been started by ABAP.
期刊最新文献
Improved, Efficient and Reliable Plant Regeneration Protocol for a Recalcitrant Black Rice (Oryza sativa cv. Chakhao amubi) Targeting Glucose Metabolism in Diabetes-A Homology Modeling and Active Site Identification for Inositol Monophosphatase Phytochemical, Toxicological, and Anti-Hyperglycemic Evaluation of Pennisetum purpureum in Sprague-Dawley Rats Biosorption of Zn (II) ion from Aqueous Solutions Using Nut Grass Dunaliella salina as a Protein Expression System for the Expression of the Endolysin Lysqdvp001 Against Vibrio parahaemolyticus
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1